Current Liabilities
Total Current Liabilities
Alnylam Pharmaceuticals Total Current Liabilities decreased by 8.0% to $1.35B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 25.5%, from $1.08B to $1.35B. Over 5 years (FY 2020 to FY 2025), Total Current Liabilities shows an upward trend with a 20.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
Metric ID:
total_current_liabilitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $554.65M | $610.66M | $695.71M | $605.96M | $657.69M | $772.79M | $767.92M | $673.39M | $788.64M | $949.79M | $967.79M | $941.71M | $1.06B | $1.22B | $1.19B | $1.08B | $1.30B | $1.56B | $1.47B | $1.35B |
| QoQ Change | — | +10.1% | +13.9% | -12.9% | +8.5% | +17.5% | -0.6% | -12.3% | +17.1% | +20.4% | +1.9% | -2.7% | +12.1% | +15.7% | -2.8% | -9.3% | +20.9% | +19.6% | -5.7% | -8.0% |
| YoY Change | — | — | — | — | +18.6% | +26.6% | +10.4% | +11.1% | +19.9% | +22.9% | +26.0% | +39.8% | +33.8% | +28.5% | +22.6% | +14.2% | +23.3% | +27.4% | +23.6% | +25.5% |
Range$554.65M – $1.56B
CAGR+20.6%
Avg YoY Growth+23.4%
Median YoY Growth+23.4%
Current Streak2 quarters decline
Total Current Liabilities at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's total current liabilities?
- Alnylam Pharmaceuticals (ALNY) reported total current liabilities of $1.35B in Q1 2026.
- How has Alnylam Pharmaceuticals's total current liabilities changed year-over-year?
- Alnylam Pharmaceuticals's total current liabilities increased by 25.5% year-over-year, from $1.08B to $1.35B.
- What is the long-term trend for Alnylam Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's total current liabilities has grown at a 20.2% compound annual growth rate (CAGR), from $585.27M to $1.47B.